3 Dow Stocks Begging to Be Bought in December_老虎社区_美港股上老虎

3 Dow Stocks Begging to Be Bought in December

Motley Fool2021-12-07

As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

269

Jialatsia
·2021-12-08
Meep
回复
点赞
举报
Dhenrish11
·2021-12-08
👍🏻👍🏻👍🏻
回复
点赞
举报
Marou
·2021-12-08
👍
回复
1
举报
MHh
·2021-12-08
Never realised that merck has animal health too!
回复
6
举报
RKT
·2021-12-08
CRM👍
回复
2
举报
收起
- JackTL:
  CRM GO
  2021-12-08
  回复
  举报
RHO
·2021-12-08
Helpful
回复
2
举报
kenong62
·2021-12-08
Please likeThanks
回复
7
举报
收起
- Sunshine_2:
  Done
  2021-12-08
  回复
  举报
- nanehz07:
  done
  2021-12-08
  回复
  举报
whitesnake
·2021-12-08
🤨
回复
4
举报
ToongMH
·2021-12-08
Good recommendation
回复
2
举报
jayfalcon
·2021-12-08
Like pls 🙏 thanks
回复
3
举报
收起
- Boo2bear:
  Liked.. Pls do the same. Tq
  2021-12-08
  回复
  举报
- kenong62:
  ok done
  2021-12-08
  回复
  举报
我i168
·2021-12-08
Got $Salesforce.com(CRM)$[Smile] [Cool]
回复
6
举报
james_l
·2021-12-08
Holding salesforce and looking at merck.
回复
3
举报
收起
- ToongMH:
  gogogo
  2021-12-08
  回复
  举报
koolgal
·2021-12-08
Of the 3 stocks I like Salesforce and Merck. They are both dominant in their fields and will grow exponentially! To the moon! 🚀🚀🚀🌙🌙🌙
回复
24
举报
收起
- koolgal:
  Thanks for your support.
  2021-12-08
  回复
  举报
- koolgal:
  Thanks for sharing.
  2021-12-08
  回复
  举报
- 56a3dd2f:
  Salesforce is great stock to own. I'm still not so convince on Verizon and Merck, shall monitor further
  2021-12-08
  回复
  举报
查看更多 2 条评论
Cockatoo
·2021-12-08
🙌
回复
4
举报
Steve81
·2021-12-08
Jiayou
回复
4
举报
Eepin
·2021-12-08
Agree on Merck
回复
4
举报
收起
- Nayazindagi:
  Great! Buy the dip ! [Like]
  2021-12-08
  回复
  举报
sc0tchb0nn3t
·2021-12-08
CRM and Merck makes sense. Verizon less compelling for me, especially given dividends will be taxed at 30% for Singaporeans
回复
10
举报
收起
- GggSlimeR:
  Makes sense
  2021-12-15
  回复
  举报
- sunshine138:
  Hawk eyes on CRM and MRK.
  2021-12-08
  回复
  举报
HENRYCSC
·2021-12-08
[Miser]
回复
3
举报
KGosti
·2021-12-08
[Miser]
回复
4
举报
收起
- KGosti:
  hoho
  2021-12-22
  回复
  举报
- KGosti:
  [Miser]
  2021-12-16
  回复
  举报
BokWoon
·2021-12-08
[Thinking]
回复
3
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2189476639?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-07 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2189476639","market":"us","top_or_hot":-1,"title":"3 Dow Stocks Begging to Be Bought in December","media":"Motley Fool","content":"<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","article_id":"2189476639","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","pubTimestamp":1638885035,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","MRK":"默沙东","BK4528":"SaaS概念","BK4516":"特朗普概念","BK4023":"应用软件","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","PFE":"辉瑞","BK4535":"淡马锡持仓","BK4559":"巴菲特持仓","BK4527":"明星科技股","BK4538":"云计算","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","CRM":"赛富时","BK4115":"综合电信业务","VZ":"威瑞森","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓"},"translate_title":"道琼斯指数的3只股票有望在12月被买进","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VZ":0.9,"PFE":0.9,"MRK":0.9,"CRM":0.9},"content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":602069887,"gmtCreate":1638941649503,"gmtModify":1638941714475,"author":{"id":"4087959350378170","authorId":"4087959350378170","name":"Jialatsia","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Meep","listText":"Meep","text":"Meep","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602069887","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":602084527,"gmtCreate":1638941382579,"gmtModify":1638941382651,"author":{"id":"4101526647376150","authorId":"4101526647376150","name":"Dhenrish11","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"👍🏻👍🏻👍🏻","listText":"👍🏻👍🏻👍🏻","text":"👍🏻👍🏻👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602084527","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606786118,"gmtCreate":1638928160640,"gmtModify":1638929648820,"author":{"id":"4101360019325200","authorId":"4101360019325200","name":"Marou","avatar":"https://static.tigerbbs.com/6ce20ff94246f13fca7d75bed86d2f38","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606786118","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606461890,"gmtCreate":1638920931415,"gmtModify":1638920934006,"author":{"id":"4091758936365950","authorId":"4091758936365950","name":"MHh","avatar":"https://static.tigerbbs.com/54b2feced9ef5dcc9e95997d1f4db280","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Never realised that merck has animal health too!","listText":"Never realised that merck has animal health too!","text":"Never realised that merck has animal health too!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606461890","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606412154,"gmtCreate":1638919594075,"gmtModify":1638919594203,"author":{"id":"3574492541167448","authorId":"3574492541167448","name":"RKT","avatar":"https://static.tigerbbs.com/4257e394d8e8b96c3ca68aa06f560402","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"CRM👍","listText":"CRM👍","text":"CRM👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606412154","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6891532,"gmtCreate":1638923209157,"gmtModify":1638923209188,"authorId":3581557493426416,"author":{"id":3581557493426416,"authorId":3581557493426416,"name":"JackTL","avatar":"https://static.tigerbbs.com/851801800e7dc3457e5e60048a987880","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606412154,"type":1,"supId":0,"prevId":0,"content":"CRM GO","text":"CRM GO","html":"CRM GO"}],"langContent":"CN"},{"id":606498516,"gmtCreate":1638917599553,"gmtModify":1638917599636,"author":{"id":"3574199287814927","authorId":"3574199287814927","name":"RHO","avatar":"https://static.tigerbbs.com/6f5c7f17ba5a1cdf54b0b606fce00581","vip":1,"crmLevel":7,"crmLevelSwitch":0},"htmlText":"Helpful","listText":"Helpful","text":"Helpful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606498516","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606490322,"gmtCreate":1638917078072,"gmtModify":1638917079961,"author":{"id":"3574928367638029","authorId":"3574928367638029","name":"kenong62","avatar":"https://static.tigerbbs.com/37fd00bd8cea11b8aa1aed6d9ddd9413","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Please likeThanks","listText":"Please likeThanks","text":"Please likeThanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606490322","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6889625,"gmtCreate":1638918751507,"gmtModify":1638918751543,"authorId":4094271730114360,"author":{"id":4094271730114360,"authorId":4094271730114360,"name":"Sunshine_2","avatar":"https://static.tigerbbs.com/c51036e171ef144f127d28c64446c582","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606490322,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":6889386,"gmtCreate":1638917981563,"gmtModify":1638917981657,"authorId":4090062734790350,"author":{"id":4090062734790350,"authorId":4090062734790350,"name":"nanehz07","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606490322,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"CN"},{"id":606407276,"gmtCreate":1638917029395,"gmtModify":1638917029564,"author":{"id":"4094787464285000","authorId":"4094787464285000","name":"whitesnake","avatar":"https://static.tigerbbs.com/86038a40c72380b34bced828cc9422b2","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"🤨","listText":"🤨","text":"🤨","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606407276","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606403088,"gmtCreate":1638915811683,"gmtModify":1638915812035,"author":{"id":"3579230468032082","authorId":"3579230468032082","name":"ToongMH","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good recommendation","listText":"Good recommendation","text":"Good recommendation","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606403088","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606574836,"gmtCreate":1638915287197,"gmtModify":1638915287504,"author":{"id":"4090418835913750","authorId":"4090418835913750","name":"jayfalcon","avatar":"https://static.tigerbbs.com/505029b8d840d52745c57c2cbf910d5c","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like pls 🙏 thanks","listText":"Like pls 🙏 thanks","text":"Like pls 🙏 thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606574836","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6890001,"gmtCreate":1638919592556,"gmtModify":1638919592649,"authorId":3578969648963961,"author":{"id":3578969648963961,"authorId":3578969648963961,"name":"Boo2bear","avatar":"https://static.tigerbbs.com/209ae746c8124fe2d5f79aee784d2fcc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606574836,"type":1,"supId":0,"prevId":0,"content":"Liked.. Pls do the same. <u>Tq</u>","text":"Liked.. Pls do the same. <u>Tq</u>","html":"Liked.. Pls do the same. <u>Tq</u>"},{"id":6889181,"gmtCreate":1638917068229,"gmtModify":1638917068258,"authorId":3574928367638029,"author":{"id":3574928367638029,"authorId":3574928367638029,"name":"kenong62","avatar":"https://static.tigerbbs.com/37fd00bd8cea11b8aa1aed6d9ddd9413","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606574836,"type":1,"supId":0,"prevId":0,"content":"ok done","text":"ok done","html":"ok done"}],"langContent":"CN"},{"id":606572352,"gmtCreate":1638914611843,"gmtModify":1638914611843,"author":{"id":"3563873670221480","authorId":"3563873670221480","name":"我i168","avatar":"https://static.tigerbbs.com/34b2d0551b5ab028c13ab35747c4df8c","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Got <a href=\"https://laohu8.com/S/CRM\">$Salesforce.com(CRM)$</a>[Smile]&nbsp;[Cool]&nbsp;","listText":"Got <a href=\"https://laohu8.com/S/CRM\">$Salesforce.com(CRM)$</a>[Smile]&nbsp;[Cool]&nbsp;","text":"Got $Salesforce.com(CRM)$[Smile] [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606572352","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606576147,"gmtCreate":1638914259189,"gmtModify":1638914259959,"author":{"id":"3563436875655076","authorId":"3563436875655076","name":"james_l","avatar":"https://static.tigerbbs.com/7960ea5c640db331ff2de0da32f6a611","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Holding salesforce and looking at merck.","listText":"Holding salesforce and looking at merck.","text":"Holding salesforce and looking at merck.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606576147","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6888891,"gmtCreate":1638915821980,"gmtModify":1638915822075,"authorId":3579230468032082,"author":{"id":3579230468032082,"authorId":3579230468032082,"name":"ToongMH","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606576147,"type":1,"supId":0,"prevId":0,"content":"<u>gogogo</u>","text":"<u>gogogo</u>","html":"<u>gogogo</u>"}],"langContent":"CN"},{"id":606579721,"gmtCreate":1638913312558,"gmtModify":1638926076639,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Of the 3 stocks I like Salesforce and Merck.&nbsp; They are both dominant in their fields and will grow exponentially! To the moon! 🚀🚀🚀🌙🌙🌙","listText":"Of the 3 stocks I like Salesforce and Merck.&nbsp; They are both dominant in their fields and will grow exponentially! To the moon! 🚀🚀🚀🌙🌙🌙","text":"Of the 3 stocks I like Salesforce and Merck. They are both dominant in their fields and will grow exponentially! To the moon! 🚀🚀🚀🌙🌙🌙","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":24,"commentSize":12,"repostSize":0,"link":"https://laohu8.com/post/606579721","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6892921,"gmtCreate":1638927235281,"gmtModify":1638927235281,"authorId":3559581955535845,"author":{"id":3559581955535845,"authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606579721,"type":1,"supId":6892024,"prevId":0,"content":"Thanks for your support.","text":"Thanks for your support.","html":"Thanks for your support."},{"id":6892910,"gmtCreate":1638927222628,"gmtModify":1638927222628,"authorId":3559581955535845,"author":{"id":3559581955535845,"authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606579721,"type":1,"supId":6892520,"prevId":0,"content":"Thanks for sharing.","text":"Thanks for sharing.","html":"Thanks for sharing."},{"id":6892520,"gmtCreate":1638926076572,"gmtModify":1638926076606,"authorId":3563664364598207,"author":{"id":3563664364598207,"authorId":3563664364598207,"name":"56a3dd2f","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606579721,"type":1,"supId":0,"prevId":0,"content":"Salesforce is great stock to own. I'm still not so convince on Verizon and Merck, shall monitor further","text":"Salesforce is great stock to own. I'm still not so convince on Verizon and Merck, shall monitor further","html":"Salesforce is great stock to own. I'm still not so convince on Verizon and Merck, shall monitor further"},{"id":6892024,"gmtCreate":1638924525393,"gmtModify":1638924525427,"authorId":3581847021927100,"author":{"id":3581847021927100,"authorId":3581847021927100,"name":"GuSen","avatar":"https://static.tigerbbs.com/1b70044f21c62e929a7c4b5157b5a273","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606579721,"type":1,"supId":0,"prevId":0,"content":"Supporting your point!","text":"Supporting your point!","html":"Supporting your point!"},{"id":6890785,"gmtCreate":1638921508139,"gmtModify":1638921508139,"authorId":3559581955535845,"author":{"id":3559581955535845,"authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":4096368443831390,"repliedAuthor":{"id":4096368443831390,"authorId":4096368443831390,"name":"b1uesky","avatar":"https://static.tigerbbs.com/87ef9b02e19a8acfaa7ae5b147b70882","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":606579721,"type":1,"supId":6889947,"prevId":6890031,"content":"Thanks for sharing your thoughts.","text":"Thanks for sharing your thoughts.","html":"Thanks for sharing your thoughts."}],"langContent":"CN"},{"id":606548890,"gmtCreate":1638909879698,"gmtModify":1638909880309,"author":{"id":"4095668241594670","authorId":"4095668241594670","name":"Cockatoo","avatar":"https://static.tigerbbs.com/0055bde0938dcc9ff3f3925ff22ea2c7","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"🙌","listText":"🙌","text":"🙌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606548890","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606548069,"gmtCreate":1638909267009,"gmtModify":1638909267319,"author":{"id":"3583228594556766","authorId":"3583228594556766","name":"Steve81","avatar":"https://static.tigerbbs.com/8451fbd9311bbb12faabfa8f6138ef34","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Jiayou","listText":"Jiayou","text":"Jiayou","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606548069","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606543814,"gmtCreate":1638907793953,"gmtModify":1638907794073,"author":{"id":"4100139672991320","authorId":"4100139672991320","name":"Eepin","avatar":"https://static.tigerbbs.com/be6504be372ba077476c43ec3530cdd9","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Agree on Merck","listText":"Agree on Merck","text":"Agree on Merck","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606543814","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6892189,"gmtCreate":1638924992833,"gmtModify":1638924992865,"authorId":4099402595795420,"author":{"id":4099402595795420,"authorId":4099402595795420,"name":"Nayazindagi","avatar":"https://static.tigerbbs.com/491906a0e23ae13ce2be00cf4d568603","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606543814,"type":1,"supId":0,"prevId":0,"content":"Great! Buy the dip !  [Like]","text":"Great! Buy the dip !  [Like]","html":"Great! Buy the dip !  [Like]"}],"langContent":"CN"},{"id":606525750,"gmtCreate":1638898511489,"gmtModify":1638898511582,"author":{"id":"4099563350842460","authorId":"4099563350842460","name":"sc0tchb0nn3t","avatar":"https://static.tigerbbs.com/b42d1995afd403d4b720e209484f8d61","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"CRM and Merck makes sense. Verizon less compelling&nbsp;for me, especially given dividends will be taxed at 30% for Singaporeans&nbsp;","listText":"CRM and Merck makes sense. Verizon less compelling&nbsp;for me, especially given dividends will be taxed at 30% for Singaporeans&nbsp;","text":"CRM and Merck makes sense. Verizon less compelling for me, especially given dividends will be taxed at 30% for Singaporeans","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606525750","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6992863,"gmtCreate":1639579293732,"gmtModify":1639579293826,"authorId":4093058604760480,"author":{"id":4093058604760480,"authorId":4093058604760480,"name":"GggSlimeR","avatar":"https://static.tigerbbs.com/19f9dd6ac1811c7e85fa95a3ea4c703e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606525750,"type":1,"supId":0,"prevId":0,"content":"Makes sense ","text":"Makes sense ","html":"Makes sense "},{"id":6888150,"gmtCreate":1638900073904,"gmtModify":1638900074005,"authorId":3586655655659820,"author":{"id":3586655655659820,"authorId":3586655655659820,"name":"sunshine138","avatar":"https://static.tigerbbs.com/23149c63a63bfeec1572cc27e1322750","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606525750,"type":1,"supId":0,"prevId":0,"content":"Hawk eyes on CRM and MRK.","text":"Hawk eyes on CRM and MRK.","html":"Hawk eyes on CRM and MRK."}],"langContent":"CN"},{"id":606564519,"gmtCreate":1638895720543,"gmtModify":1638895721164,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606564519","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606566903,"gmtCreate":1638895064008,"gmtModify":1638895064092,"author":{"id":"3563080940277680","authorId":"3563080940277680","name":"KGosti","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606566903","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7069103,"gmtCreate":1640108166621,"gmtModify":1640108166646,"authorId":3563080940277680,"author":{"id":3563080940277680,"authorId":3563080940277680,"name":"KGosti","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606566903,"type":1,"supId":0,"prevId":0,"content":"<u>hoho</u>","text":"<u>hoho</u>","html":"<u>hoho</u>"},{"id":7000277,"gmtCreate":1639622319322,"gmtModify":1639622319346,"authorId":3563080940277680,"author":{"id":3563080940277680,"authorId":3563080940277680,"name":"KGosti","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606566903,"type":1,"supId":0,"prevId":0,"content":"[Miser]","text":"[Miser]","html":"[Miser]"}],"langContent":"CN"},{"id":606584305,"gmtCreate":1638893767541,"gmtModify":1638893767786,"author":{"id":"3586346457808493","authorId":"3586346457808493","name":"BokWoon","avatar":"https://static.tigerbbs.com/33c54abe9712d43f005ec31ac4eb5e90","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"[Thinking]&nbsp;","listText":"[Thinking]&nbsp;","text":"[Thinking]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606584305","repostId":2189476639,"repostType":4,"repost":{"id":"2189476639","pubTimestamp":1638885035,"share":"https://www.laohu8.com/m/news/2189476639?lang=&edition=full","pubTime":"2021-12-07 21:50","market":"us","language":"en","title":"3 Dow Stocks Begging to Be Bought in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2189476639","media":"Motley Fool","summary":"Growth, value, and income investors all have a stock that's ripe for the picking.","content":"<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic <b>Dow Jones Industrial Average</b> (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.</p>\n<p>But just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/789196b3d59ea758b03121ea67790d5a\" tg-width=\"700\" tg-height=\"484\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/CRM\">Salesforce</a></h2>\n<p>For growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider <b>Salesforce.com</b> (NYSE:CRM).</p>\n<p>Like most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed <a href=\"https://laohu8.com/S/WORK\">Slack Technologies</a> acquisition.</p>\n<p>While these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.</p>\n<p>CRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.</p>\n<p>Salesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.</p>\n<p>Growth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.</p>\n<p>With Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/467adad2d31104b83afa51e5b1425137\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Merck</h2>\n<p>Value investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock <b>Merck</b> (NYSE:MRK) are now begging to be bought.</p>\n<p>\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of <b>Pfizer</b>'s (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.&nbsp; Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.</p>\n<p>But here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.</p>\n<p>The front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.</p>\n<p>The other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.</p>\n<p>Following its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb0880fa9f40b9af4d310e1390a18754\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Verizon</h2>\n<p>Finally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth <b>Verizon</b> (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.</p>\n<p>There look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.</p>\n<p>But similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.</p>\n<p>Despite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.</p>\n<p>The other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.</p>\n<p>Verizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dow Stocks Begging to Be Bought in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dow Stocks Begging to Be Bought in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4535":"淡马锡持仓","PFE":"辉瑞","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4115":"综合电信业务","CRM":"赛富时","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","VZ":"威瑞森","BK4548":"巴美列捷福持仓","BK4516":"特朗普概念","BK4528":"SaaS概念","BK4023":"应用软件","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","MRK":"默沙东","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/07/3-dow-stocks-begging-to-be-bought-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189476639","content_text":"As you've probably noticed, volatility has picked up in a big way over the past two weeks. But don't let this distract from the fact that the iconic Dow Jones Industrial Average (DJINDICES:^DJI) has had a stellar year. Through this past weekend, the price-weighted index comprised of 30 multinational companies was up about 13%.\nBut just because the Dow, as a whole, has done well in 2021, it doesn't mean bargains can't be found. At the moment, there are three Dow stocks absolutely begging to be bought by growth, value, or income investors in December.\nImage source: Getty Images.\nSalesforce\nFor growth investors, there's little question that the Dow stock to back the truck up on in December is cloud-based customer relationship management (CRM) solution provider Salesforce.com (NYSE:CRM).\nLike most growth stocks that have been valued at a premium, Salesforce took it on the chin following its fiscal third quarter 2022 operating results, which were released last week. Though Wall Street seemed pleased with the recently completed quarter, the company's sales guidance for fiscal 2023 was essentially in-line with expectations. Since Salesforce has a habit of upping its sales forecast, investors appear worried about a growth slowdown and/or higher near-term costs associated with the recently completed Slack Technologies acquisition.\nWhile these might sound like tangible concerns, they're very short-sighted and don't affect the long-term growth trajectory for Salesforce.\nCRM software is a sustainable double-digit growth opportunity through at least the midpoint of this decade, if not well beyond. CRM software, which helps consumer-facing businesses enhance existing client relationships and improve sales, is a no-brainer solution for most service industry companies, but is quickly gaining utility in the financial, healthcare, and industrial sectors.\nSalesforce sits on a pedestal within the CRM software space, and no other company even comes close. When IDC examined global CRM spending for 2020, it found that Salesforce accounted for 19.5% of worldwide revenue. That's more than the four closest competitors behind it on a combined basis. This suggests the company isn't going to lose its competitive edge anytime soon.\nGrowth investors will also appreciate CEO Marc Benioff's penchant for acquisitions. Key buyouts, such as MuleSoft, Tableau, and Slack, have expanded the usefulness of the Salesforce ecosystem, allowed the company to cross-sell its solutions on diverse platforms, and helped it reach a wider array of small-and-medium-sized businesses.\nWith Benioff expecting full-year sales to grow from $21.3 billion to at least $50 billion in a five-year stretch, any significant pullback in Salesforce's shares represents a surefire buying opportunity.\nImage source: Getty Images.\nMerck\nValue investors, this one's for you! Following a nearly 20% sell-off over the past month, shares of pharmaceutical stock Merck (NYSE:MRK) are now begging to be bought.\n\"Why the sell-off?\" you ask? The answer probably has to do with the early November-released trial results of Pfizer's (NYSE:PFE) COVID-19 oral antiviral treatment. Based on an interim analysis of a phase 2/3 trial, this oral treatment reduced the risk of hospitalization or death by 89% in non-hospitalized adult patients with COVID-19. Meanwhile, Merck's oral COVID-19 pill reduced the risk of hospitalization or death by approximately 50% in COVID-19 patients.  Though these treatments weren't pitted head-to-head, the nominal efficacy award looks to go to Pfizer -- at least based on how investors have reacted since the data release.\nBut here's the thing: Merck was worth buying well before it delivered encouraging phase 3 results from its oral antiviral study in COVID-19 patients. In fact, COVID-19 treatments don't even need to play a role for Merck to head higher, in my opinion.\nThe front-and-center reason to be excited about Merck's future is cancer immunotherapy Keytruda. Based on the $4.53 billion in sales generated from Keytruda in the third quarter, it's on pace for more than $18 billion in annual run-rate revenue. If we exclude COVID-19 vaccines, this would make it the second best-selling drug in the world, behind only anti-inflammatory drug Humira. Keytruda is being examined in a number of additional trials (mostly as a combination treatment), which could further expand its label and make it the top-selling non-vaccine drug in the world.\nThe other exciting growth trend Merck offers is its animal health division. Its focus on both livestock and companion animals has yielded consistent double-digit sales growth. But between the two, companion animals, such as cats and dogs, offer more upside. Year-over-year spending on pets in the U.S. hasn't declined in over a quarter of a century, and pet owners have shown they'll spend whatever is necessary to ensure the well-being of their furry family members.\nFollowing its recent tumble, Merck shares are now valued at a multiple of just 10 times Wall Street's forecasted earnings per share in 2022. That's a bargain for a company delivering steady sales growth.\nImage source: Getty Images.\nVerizon\nFinally, for income investors, the third Dow stock begging to be bought in December is telecom behemoth Verizon (NYSE:VZ). Shares are down a hair over 10% in the trailing six-month period.\nThere look to be two reasons why Verizon is down on its luck in recent months. First, investors have predominantly favored growth stocks over mature income plays. And second, Verizon has had to spend big on spectrum and infrastructure upgrades, which means it's carrying around quite a bit of debt. This debt could be keeping some investors on the sideline.\nBut similar to Salesforce, the worries surrounding Verizon look to be either overblown or short-term in nature. The company has generated over $40 billion in operating cash flow over the trailing 12 months, and its dividend payout ratio is below 50%. Based on its balance sheet, Verizon's 5% yield is sustainable and its debt servicing is manageable.\nDespite being a mature business, Verizon has two organic growth catalysts that could fuel modest upside through mid-decade. First, there's the ongoing rollout of 5G wireless infrastructure. It's been a decade since wireless download speeds were meaningfully improved. The rollout of 5G should lead to a multiyear device upgrade cycle with a steady increase in data consumption. Since data is where Verizon derives its juiciest wireless margins, 5G infrastructure investments should begin paying off handsomely very soon.\nThe other key growth driver for Verizon is in-home fixed wireless broadband services. Verizon has been an aggressive acquirer of 5G mid-band spectrum in 2021. The expectation is that Verizon can double the number of households it's servicing with fixed wireless broadband services from 15 million in 2021 to 30 million by the end of 2023.\nVerizon may not be the growth story it once was, but a 5% dividend yield and price-to-earnings ratio of a little over nine make it ripe for the picking.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":269,"commentSize":30,"repostSize":0,"favoriteSize":4,"likeStatus":false,"favoriteStatus":false}}